Personal-Use Self-monitoring Blood Glucose Devices Market Size and Share

Personal-Use Self-monitoring Blood Glucose Devices Market Analysis by Mordor Intelligence
The personal-use self-monitoring blood glucose devices market size reached USD 4.40 billion in 2025 and is forecast to touch USD 6.10 billion by 2030, advancing at a 6.75% CAGR during the period. The expansion reflects the compound effect of rising diabetes prevalence, population aging, and steady reimbursement gains for connected meters. Continuous sensor innovation, smartphone integration, and over-the-counter (OTC) clearances broaden the addressable base beyond insulin-dependent patients, while real-time analytics improve therapeutic decision-making. Growth also benefits from expanding wellness adoption among non-diabetic consumers and sustained venture funding that accelerates miniaturized, low-power designs. Competitive intensity remains moderate but is sharpening as scale players link glucose data with automated insulin delivery, digital coaching, and generative AI platforms.
Key Report Takeaways
- By component, test strips led with 65.25% of personal-use self-monitoring blood glucose devices market share in 2024, whereas glucometer devices are set to post the fastest 9.25% CAGR to 2030.
- By technology, self-monitoring blood glucose accounted for 35.53% revenue share in 2024, while continuous glucose monitoring is poised to rise at a 12.35% CAGR.
- By connectivity, Bluetooth commanded 43.82% revenue share in 2024; near-field communication is projected to climb at an 11.26% CAGR through 2030.
- By end-user, the home-care segment represented 88.82% of industry revenue in 2024, while sports and wellness users are forecast to expand at 11.62% CAGR.
- By geography, North America held 42.82% revenue share in 2024, yet Asia-Pacific is on track for the quickest 12.62% CAGR to 2030.
Global Personal-Use Self-monitoring Blood Glucose Devices Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Rising Diabetes Prevalence & Ageing Population | +1.8% | Global, with highest impact in APAC and MEA | Long term (≥ 4 years) |
Smartphone-Linked Smart Meters Gain Reimbursement Traction | +1.2% | North America & EU, expanding to APAC | Medium term (2-4 years) |
Expansion Of Continuous & Flash GM Into Type-2 Pre-Diabetes | +1.5% | Global, led by developed markets | Medium term (2-4 years) |
OTC Approval Of Non-Invasive Optical Meters | +0.9% | North America & EU regulatory frameworks | Short term (≤ 2 years) |
Wellness Wearables Drive Adoption By Non-Diabetics | +0.8% | Global, concentrated in urban centers | Short term (≤ 2 years) |
Source: Mordor Intelligence
Rising Diabetes Prevalence & Ageing Population
Global diabetes prevalence could exceed 783.2 million by 2045, creating sustained demand for easy-to-use monitors[3]Centers for Disease Control and Prevention, “IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045,” stacks.cdc.gov. The burden is pronounced in Asia-Pacific, where China already records a 13.67% prevalence and faces a projected 29.1% rate by 2050. Older adults need simplified interfaces, larger displays, and dependable connectivity, prompting manufacturers to refine ergonomy and voice-guided prompts. Combined demographic and disease pressures ensure that the personal-use self-monitoring blood glucose devices market continues expanding even in reimbursement-constrained settings. The sheer volume of potential users underpins long-run volume growth that can absorb price erosion.
Smartphone-Linked Smart Meters Gain Reimbursement Traction
Medicare aligned coverage rules with ADA guidance in 2023, waiving finger-stick confirmation and adding basal-only Type 2 patients, thereby subsidizing 80% of approved CGM system costs[2]Sean M. Oser & Tamara K. Oser, “Medicare Coverage of Continuous Glucose Monitoring — 2023 Updates,” aafp.org. Commercial payers quickly followed, citing documented A1c reductions and reduced hypoglycemia events. In Europe, Norway and Belgium introduced national funding for sensor-based monitors, while additional markets evaluate similar moves. Reimbursement cuts out-of-pocket cost, fostering mainstream adoption and enabling vendors to bundle smartphones, apps, and cloud portals. As insurers link sensor data with population-health analytics, reimbursement remains a decisive pull factor for the personal-use self-monitoring blood glucose devices market.
Expansion of Continuous & Flash GM Into Type-2 Pre-Diabetes
Clinical trials show continuous monitoring reduces HbA1c even in non-insulin Type 2 cohorts, supporting coverage expansion and primary-care uptake. Public health authorities now study cost-effectiveness findings that place CGM within accepted willingness-to-pay thresholds for basal-only users. Pre-diabetic and wellness users number near 720 million globally, representing an untapped market for early metabolic feedback. Consumer platforms such as Ultrahuman demonstrate how lifestyle analytics motivate dietary adjustments among healthy individuals. These dynamics pull continuous sensors deeper into primary prevention, broadening the commercial base for the personal-use self-monitoring blood glucose devices market.
OTC Approval of Non-Invasive Optical Meters
The FDA cleared Dexcom’s Stelo and Abbott’s Lingo as the first OTC CGMs in 2024, erasing prescription barriers[1]U.S. Food and Drug Administration, “FDA Clears First Over-the-Counter Continuous Glucose Monitor,” fda.gov. Device makers now sell directly through pharmacies and e-commerce, reaching early stage diabetics and wellness consumers. Optical sensing studies show Raman-based prototypes hitting 12.8% MARD, approaching clinical-grade accuracy. OTC access reshapes marketing, emphasizes intuitive apps, and supports subscription revenue. Rapid consumer uptake accelerates data volumes, enabling personalized coaching and fueling competitive pressure across the personal-use self-monitoring blood glucose devices market.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
High Lifetime Cost Of Consumables (Strips / Sensors) | -1.4% | Global, most acute in emerging markets | Long term (≥ 4 years) |
Accuracy Gaps Vs. Lab Reference In Tropical Climates | -0.8% | Tropical regions, APAC, MEA, South America | Medium term (2-4 years) |
Cyber-Security & Data-Privacy Regulations Tighten | -0.6% | Global, led by North America & EU enforcement | Short term (≤ 2 years) |
Source: Mordor Intelligence
High Lifetime Cost of Consumables (Strips / Sensors)
Annual CGM ownership ranges between USD 1,200 and USD 3,600, while 100-count strip boxes retail from USD 35 to USD 170, squeezing uninsured and low-income users. Even Dexcom’s value-priced Stelo still averages USD 100 per month. Surveys across six developing countries confirm affordability gaps that dampen sustained monitoring adherence. Manufacturers respond with longer-life sensors and bundle discounts, yet volume-driven cost declines remain gradual. Without broader subsidies, consumable burden continues to temper uptake in price-sensitive segments of the personal-use self-monitoring blood glucose devices market.
Accuracy Gaps vs. Lab Reference in Tropical Climates
Heat and humidity can induce up to 30.1% error within minutes, undermining clinical confidence in warm regions. Hospital studies in Thailand and the Philippines report systematic variance during monsoon months, forcing labor-intensive stress testing. Strip enzymes degrade under oscillating temperature cycles, while sensor membranes suffer moisture intrusion. Vendors are redesigning packaging and electronic shielding, yet field reliability lags lab benchmarks. Persistent accuracy concerns slow guideline endorsement and constrain the personal-use self-monitoring blood glucose devices market in equatorial economies.
Segment Analysis
By Component: Consumables Continue to Anchor Revenue
Test strips captured 65.25% of the personal-use self-monitoring blood glucose devices market in 2024, preserving a high-margin replenishment stream that underwrites manufacturer cash flows. Devices, however, are registering the quickest 9.25% CAGR as users pivot to integrated, sensor-rich platforms that lower per-reading cost over time. Longer wear sensors such as Dexcom G7 15-Day demonstrate how hardware upgrades decrease monthly spend and improve convenience. Accessories—from lancet drums to smartphone cradles—command modest but rising revenue as connectivity and comfort influence brand choice.
Glucometer innovation now targets single-platform ecosystems that pair proprietary sensors with AI-driven apps. Abbott’s FreeStyle Libre 2 Plus, the first U.S. CGM to link directly with automated insulin delivery, illustrates the hardware-software convergence reshaping the personal-use self-monitoring blood glucose devices market. Vendors also trial reusable optical readers designed to leverage strip-free photonics, potentially compressing consumable demand. While strips remain dominant, incremental sensor advances steadily shift revenue weight toward durable equipment and cloud subscriptions.
Note: Segment shares of all individual segments available upon report purchase
By Technology: Continuous Monitoring Disrupts SMBG Hegemony
Self-monitoring blood glucose still holds 35.53% share, anchored by affordability and clinician familiarity. Nevertheless, continuous sensors are outpacing at 12.35% CAGR because real-time trend data reduce hypoglycemia risk and support dose titration. Randomized studies in primary care show CGM users achieving HbA1c drops of 1.3 percentage points versus 0.8 points for finger-stick cohorts. Non-invasive optical prototypes demonstrate accelerating accuracy gains, aided by machine-learning spectroscopic algorithms.
Technology suppliers bundle sensors with telehealth dashboards, broadening clinical oversight and unlocking insurer value-based payments. Medtronic’s Simplera disposable CGM, half the size of its predecessor, shows how form-factor reductions drive comfort and adoption. As reimbursement spreads and component costs fall, CGM looks set to erode SMBG leadership across the personal-use self-monitoring blood glucose devices market.
By Connectivity: Bluetooth Reigns While NFC Accelerates
Bluetooth retained 43.82% revenue share in 2024, benefitting from universal smartphone support and established pairing stacks. Near-field communication, however, is projected to grow 11.26% annually because it permits tap-to-scan uploads without user configuration. NFC chips also consume less power, extending sensor life and fostering fully disposable designs. USB and proprietary cables linger for clinical download stations but fade in consumer channels.
Connectivity now underpins analytics differentiation. Dexcom recently launched the first glucose biosensing generative-AI platform on Google Vertex AI, a move that demands stable, low-latency data links. NFC’s simplicity supports elderly users and emerging-market customers who rely on entry-level Android phones, expanding penetration of the personal-use self-monitoring blood glucose devices market.

Note: Segment shares of all individual segments available upon report purchase
By End-User: Home-Care Dominates Yet Wellness Surges
Home-care applications represented 88.82% of revenue in 2024, reflecting the day-to-day nature of diabetes self-management. Retail OTC approvals now allow walk-in purchase, bolstering household adoption. Simultaneously, sports and wellness users are forecast for an 11.62% CAGR as athletes and weight-loss seekers adopt CGMs to fine-tune diet and training. A multi-armed study on non-diabetic Indians using Ultrahuman’s platform illustrated how real-time glucose curves encourage healthier meal choices.
Mainstream media coverage has normalized CGM for metabolic awareness, though data literacy gaps persist. Manufacturers counter by embedding color-coded insights and automated food logging. Wellness adoption thus diversifies revenue and creates a preventive front door for the personal-use self-monitoring blood glucose devices market.
Geography Analysis
North America led the personal-use self-monitoring blood glucose devices market with 42.82% revenue share in 2024 on the back of payer funding, early tech uptake, and robust distribution networks. Medicare’s expanded coverage and successive private-payer updates have widened eligibility for continuous sensors, spurring double-digit unit growth. The U.S. FDA’s friendly stance toward OTC clearances further enlarges the consumer funnel and shortens go-to-market cycles. Canada mirrors these trends, advancing national reimbursement pilots for flash sensors.
Asia-Pacific is projected to log a 12.62% CAGR through 2030 as high prevalence converges with rising middle-class disposable income. China’s digital health programs demonstrate that integrated platforms can trim fasting glucose by 1.68% and HbA1c by 0.45 points among engaged users. India’s uptake of point-of-care HbA1c screening, with an ICUR of just USD 185.10/QALY in rural settings, underscores economic viability. Government initiatives to localize sensor assembly are also likely to shrink end-user prices, fuelling further expansion of the personal-use self-monitoring blood glucose devices market.
Europe maintains stable mid-single-digit growth, underpinned by national funding steps such as Norway’s 2023 decision to reimburse sensor-based monitors. The EU’s Medical Device Regulation harmonizes safety benchmarks, favoring firms with rigorous quality systems. Meanwhile, Latin America and Middle East-Africa show rising incidence but adoption lags due to cost and limited payer coverage. Nevertheless, philanthropic procurement and telehealth pilots in Gulf Cooperation Council states foreshadow incremental upside.

Competitive Landscape
Competition centers on technology leadership, integrated ecosystems, and regulatory agility. Abbott, Dexcom, and Roche collectively anchor the top tier, each leveraging data platforms to lock in users. Abbott’s August 2024 agreement with Medtronic links FreeStyle Libre sensors with automated insulin pumps, broadening closed-loop care. Dexcom counters through AI-driven insight engines that personalize coaching and flag glycemic excursions in real time.
Mid-cap players pursue white-space. Glucotrack advanced an implantable monitor through first-in-human trials, potentially eliminating external wearables. Tandem Diabetes Care signed a June 2025 pact with Abbott to incorporate dual glucose-ketone sensing into its automated delivery portfolio. Such alliances consolidate data streams, complicate entrant differentiation, and heighten switching costs in the personal-use self-monitoring blood glucose devices market.
Regulatory standards raise technical hurdles. The May 2025 FDA rule (21 CFR 862.1355) codified accuracy and cybersecurity criteria for integrated systems, prompting heavy investment in quality assurance. Vendors that meet these bars gain first-mover market access, while laggards risk reimbursement exclusion. As platform convergence intensifies, channel leverage and data-analytics capability are expected to determine share shifts over the next five years.
Personal-Use Self-monitoring Blood Glucose Devices Industry Leaders
-
LifeScan Inc.
-
Arkray Inc.
-
Ascensia Diabetes Care Holdings AG
-
F. Hoffmann-La Roche AG
-
Abbott Laboratories
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- January 2025: PT Diagnostics introduced the A1CNow SELF CHECK in the UK, enabling individuals to monitor diabetes in just five minutes at home.
- June 2024: Abbott secured FDA clearance for Lingo, an OTC CGM aimed at both diabetes and general wellness audiences.
Global Personal-Use Self-monitoring Blood Glucose Devices Market Report Scope
Personal use self-monitoring of blood glucose is an approach used by diabetic patients to measure their blood sugar level themselves using a glucometer, test strips, and lancets at home setting. Based on the readings, patients can adjust or check the effect of their treatment.
The self-monitoring blood glucose device market is segmented into components and geography. By component, the market is further sub-segmented into Glucometer Devices, Test Strips, and Lancet. By Geography, the market is subsegmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. The report offers the value (in USD) for the above segments.
By Component | Glucometer Devices | ||
Test Strips | |||
Lancets | |||
Accessories | |||
By Technology | SMBG (Capillary) | ||
Continuous Glucose Monitoring (Personal) | |||
Non-Invasive Optical Monitoring | |||
By Connectivity | Wired / USB | ||
Bluetooth / BLE | |||
NFC | |||
By End-User | Home-Care / Personal | ||
Sports & Wellness Users | |||
Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
South Korea | |||
Australia | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Glucometer Devices |
Test Strips |
Lancets |
Accessories |
SMBG (Capillary) |
Continuous Glucose Monitoring (Personal) |
Non-Invasive Optical Monitoring |
Wired / USB |
Bluetooth / BLE |
NFC |
Home-Care / Personal |
Sports & Wellness Users |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
South Korea | |
Australia | |
Rest of Asia-Pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the current size of the personal-use self-monitoring blood glucose devices market?
The market stands at USD 4.40 billion in 2025 and is projected to reach USD 6.10 billion by 2030.
Which component category generates the most revenue?
Test strips lead with 65.25% market share in 2024, anchoring recurring revenue.
How fast is continuous glucose monitoring (CGM) growing?
CGM is advancing at a 12.35% CAGR through 2030, the quickest pace among technology segments.
Which region is expanding the fastest?
Asia-Pacific is forecast to grow at a 12.62% CAGR on the back of rising diabetes prevalence and healthcare investments.
What recent regulatory move is boosting consumer adoption?
The FDA’s 2024 OTC clearance of devices like Dexcom’s Stelo and Abbott’s Lingo removed prescription barriers and widened access.